Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher, Janssen Biotech to Develop CDx for Lung Cancer, Other Indications

NEW YORK – Thermo Fisher Scientific said on Thursday that it has teamed up with Janssen Biotech, a member of Johnson & Johnson's Janssen Pharmaceutical Companies, to develop a companion diagnostic test to support clinical trial enrollment of cancer patients.

Under the deal, scientists at Thermo Fisher and Janssen Research & Development will initially validate biomarkers for use with the Thermo Fisher Oncomine Dx Target Test to identify non-small cell lung cancer (NSCLC) patients for enrollment into clinical trials. The firms may add other cancer indications later on.

The Oncomine Dx Target Test is a next-gen sequencing assay that covers 46 cancer biomarkers. It was approved by the US Food and Drug Administration as a CDx for NSCLC in 2017 and requires only small amounts of DNA or RNA, according to the company.

Since then, Thermo Fisher has struck agreements with several pharmaceutical firms, including Eli Lilly, Daiichi Sankyo, and Takeda Pharmaceuticals, to use the test as a CDx in clinical trials and drug development programs.

"We are confident that this approach to patient stratification helps expedite drug development initiatives which ultimately are designed to promote better health outcomes through targeted therapies," said Peter Silvester, senior VP and president of life sciences solutions at Thermo Fisher Scientific, in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.